Income tax expense/(benefit)

12 Months Ended

Dec. 31, 2024

Income tax expense/(benefit) [Abstract]

Income tax expense/(benefit)

11. Income tax expense/(benefit)

11.1. Income tax expense/(benefit)

	2024			2023			2022
		A$’000			A$’000			A$’000
Current tax expense1		32,422			14,357			9,428
Deferred tax benefit		(26,285	)		(16,481	)		(3,971	)
		6,137			(2,124	)		5,457

1. The current tax expense is attributable to Telix Innovations SA and Telix Pharmaceuticals US Inc and is driven by the individual entity’s taxable profits.

11.2. Numerical reconciliation of prima facie tax payable to income tax expense/(benefit)

	2024			2023			2022
		A$’000			A$’000			A$’000
Profit/(loss) before income tax		56,056			3,087			(98,622	)
Prima-facie tax at a rate of 30.0% (2023: 30.0%, 2022: 30.0% )		16,817			926			(29,587	)
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:
Net R&D tax incentive credit		(20,939	)		(7,408	)		(6,688	)
Remeasurement of provisions		7,441			13,915			7,423
Share-based payments expense		153			2,636			2,434
Employee Share Trust payments		(2,124	)		(10,776	)		(8,073	)
Sundry items		562			569			2
Foreign exchange translation loss		-			1,028			(464	)
		1,910			890			(34,953	)
Current year tax losses not recognized		61,409			35,152			46,325
Prior year tax losses recognized		-			-			(854	)
Adjustment for current tax of prior periods		-			-			561
Difference in overseas tax rates		(57,182	)		(38,166	)		(5,622	)
Income tax (benefit)/expense		6,137			(2,124	)		5,457